Head-To-Head Survey: Faron Pharmaceuticals Oy (OTC:FPHAF) & Hyperion DeFi (NASDAQ:HYPD)

Hyperion DeFi (NASDAQ:HYPD) and Faron Pharmaceuticals Oy (OTC:FPHAF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Profitability

This table compares Hyperion DeFi and Faron Pharmaceuticals Oy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-119.59%	-68.88%
Faron Pharmaceuticals Oy	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Hyperion DeFi and Faron Pharmaceuticals Oy, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1	2	2	0	2.20
Faron Pharmaceuticals Oy	0	0	0	0	0.00

Hyperion DeFi presently has a consensus target price of $4.58, suggesting a potential upside of 50.27%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, research analysts plainly believe Hyperion DeFi is more favorable than Faron Pharmaceuticals Oy.

Valuation and Earnings

This table compares Hyperion DeFi and Faron Pharmaceuticals Oy”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$60,000.00	415.31	-$49.82 million	($4.04)	-0.75
Faron Pharmaceuticals Oy	N/A	N/A	N/A	N/A	N/A

Faron Pharmaceuticals Oy has lower revenue, but higher earnings than Hyperion DeFi.

Institutional and Insider Ownership

25.8% of Hyperion DeFi shares are held by institutional investors. 10.9% of Hyperion DeFi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Hyperion DeFi beats Faron Pharmaceuticals Oy on 6 of the 8 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. It also develops Haematokine, an investigational AOC3 inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. In addition, the company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.